The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...

The US Food and Drug Administration (FDA) yesterday approved Abrysvo (respiratory syncytial virus vaccine). Developed and ...

Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the ...

The Food and Drug Administration (FDA) has approved Abrysvo ® (respiratory syncytial virus [RSV] vaccine) for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by ...

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.

Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration approved ABRYSVO (Respiratory Syncytial Virus Vaccine), the ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will expand the number of people eligible for ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...